Scientists recently studied how different factors affect antisense oligonucleotides (ASOs) under hydrophilic interaction ...

As part of the agreement, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up to $27.5m.

Alloy Therapeutics Announces a Target Specific Collaboration and License Agreement for use of AntiClastic TM Antisense ...